121 related articles for article (PubMed ID: 8120548)
1. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
Gianni AM; Tarella C; Bregni M; Siena S; Lombardi F; Gandola L; Caracciolo D; Stern A; Bonadonna G; Boccadoro M
J Clin Oncol; 1994 Mar; 12(3):503-9. PubMed ID: 8120548
[TBL] [Abstract][Full Text] [Related]
2. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
4. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
[TBL] [Abstract][Full Text] [Related]
5. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
6. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
9. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
Long GD; Chao NJ; Hu WW; Negrin RS; Wong RM; Blume KG
Cancer; 1996 Dec; 78(12):2502-9. PubMed ID: 8952558
[TBL] [Abstract][Full Text] [Related]
10. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells.
Gianni AM; Tarella C; Siena S; Bregni M; Boccadoro M; Lombardi F; Bengala C; Bonadonna G; Pileri A
Bone Marrow Transplant; 1990 Aug; 6(2):143-5. PubMed ID: 1976399
[TBL] [Abstract][Full Text] [Related]
11. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
12. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
Caracciolo D; Gavarotti P; Aglietta M; Bondesan P; Falda M; Gallo E; Locatelli F; Novarino A; Paolino F; Sanavio F
Bone Marrow Transplant; 1993 Dec; 12(6):621-5. PubMed ID: 7907906
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Tarella C; Boccadoro M; Omedé P; Bondesan P; Caracciolo D; Frieri R; Bregni M; Siena S; Gianni AM; Pileri A
Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF.
Majolino I; Marcenò R; Buscemi F; Scimè R; Vasta S; Indovina A; Pampinella M; Catania P; Santoro A
Haematologica; 1995; 80(2):108-14. PubMed ID: 7543068
[TBL] [Abstract][Full Text] [Related]
15. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
Schenkein DP; Koc Y; Alcindor T; Stadtmauer EA; Miller KB; Cooper BW; Partridge AH; Lazarus HM
Biol Blood Marrow Transplant; 2000; 6(4A):448-55. PubMed ID: 10975514
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
19. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
20. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
